Parse Biosciences, a Qiagen unit, partnered with bit.bio to build a map of transcription factor-driven cell identity, spanning cell state and cell fate. The collaboration combines bit.bio’s cell programming technology (Opti-ox) and discovery platform (Cell Foundry) with Parse’s scalable single-cell assays (Evercode) to test thousands of genetic variables against cell behavior. Both companies framed the work as a foundation dataset to support AI-driven therapy design and human cell manufacturing. For the cell therapy and precision medicine ecosystem, the operational milestone is linking transcription factor perturbations to reproducible cellular outputs at scale. The near-term signal for development teams is how quickly these datasets can feed modeling pipelines used for predictive medicine workflows and manufacturing strategies for engineered cell products.